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Abstract
Fragile X syndrome (FXS) is a leading cause of intellectual disability. FXS is caused by loss of function of the FMR1
gene, and mice in which Fmr1 has been inactivated have been used extensively as a preclinical model for FXS. We
investigated the behavioral pharmacology of drugs acting through dopaminergic, glutamatergic, and cholinergic
systems in fragile X (Fmr1-/Y) mice with intracranial self-stimulation (ICSS) and locomotor activity measurements. We
also measured brain expression of tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine biosynthesis.
Fmr1-/Y mice were more sensitive than wild type mice to the rewarding effects of cocaine, but less sensitive to its
locomotor stimulating effects. Anhedonic but not motor depressant effects of the atypical neuroleptic, aripiprazole,
were reduced in Fmr1-/Y mice. The mGluR5-selective antagonist, 6-methyl-2-(phenylethynyl)pyridine (MPEP), was
more rewarding and the preferential M1 antagonist, trihexyphenidyl, was less rewarding in Fmr1-/Y than wild type
mice. Motor stimulation by MPEP was unchanged, but stimulation by trihexyphenidyl was markedly increased, in
Fmr1-/Y mice. Numbers of midbrain TH+ neurons in the ventral tegmental area were unchanged, but were lower in the
substantia nigra of Fmr1-/Y mice, although no changes in TH levels were found in their forebrain targets. The data are
discussed in the context of known changes in the synaptic physiology and pharmacology of limbic motor systems in
the Fmr1-/Y mouse model. Preclinical findings suggest that drugs acting through multiple neurotransmitter systems
may be necessary to fully address abnormal behaviors in individuals with FXS.
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Introduction
Fragile X syndrome (FXS) is the most common inherited
cause of intellectual disability and the most common single-
gene defect identified in autism [1]. Approximately one-third of
patients with FXS are eventually diagnosed with autism
spectrum disorder [2], and it is estimated that up to 6-8% of
children diagnosed with autism carry mutations in the X-linked
FMR1 gene [3]. Patients with FXS often have deficits in verbal
and performance skills, spatial reasoning, and short term
memory, as well as attention deficits and hyperactivity,
stereotypic movements, and atypical social development [4-7].
FXS results from inappropriate transcriptional silencing of the
FMR1 gene [8] and failure to express its product, FMRP (fragile
X mental retardation protein), an RNA-binding protein that
represses local protein synthesis [9]. Mice lacking the Fmr1
gene model aspects of the pathophysiology and many of the
abnormal behaviors seen in FXS and autism, including
cognitive impairments [10-13], increased spontaneous motor
activity [14-16] (but see 17,18), increased seizure susceptibility
[19,20]; and altered social behaviors [17,21-23].
FMRP opposes signaling through G protein-coupled
receptors (GPCRs) acting through the Gqα-subunit, including
group I metabotropic glutamate (mGluR1/5) and M1 muscarinic
acetylcholine (mAChR1) receptors. Gq-coupled GPCRs signal
through phospholipase-C (PLC) and phosphoinositide 3-kinase
(PI3K), influencing local protein synthesis through both the Akt/
mTOR and MEK/ERK pathways (reviewed in 24). In dendritic
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spines, activity at these receptors in response to stimuli
facilitates local synaptic protein translation; and lack of FMRP
therefore leads to abnormally exaggerated experience and
protein synthesis-dependent synaptic plasticity [25-28]. Spine
development is impaired such that spines are longer and
thinner, retaining a more immature form, and do not undergo
normal experience-dependent modification of size, shape, or
number [29,30]. PLC signaling is important in activity-
dependent spine development, supporting findings that mGluR
antagonists normalize spine morphology in fmr1-null mice
[31,32]. Heterodimeric D1/D2 dopamine receptors also activate
PLC through Gq [33,34], but whether this signaling mechanism
is affected in Fmr1-null mice is not yet known.
Although the pathophysiological mechanisms in FXS are
some of the most understood among the genetic
synaptopathies, therapy for this disorder currently consists of
symptom management and not pharmacological correction or
reversal of synaptic changes due to loss of FMRP. Both
mAChR and mGluR-dependent LTD is enhanced in
hippocampal neurons [28]. Antagonism of mGluRs has been
proposed as a rational therapy for FXS [35], and preclinical
studies have shown that mGluR5 antagonists can partially
correct some abnormal behaviors in Fmr1-null mice, including
increased open-field exploration, impaired rotarod
performance, and decreased prepulse inhibition, although
results have been mixed [18,36,37]. While still under clinical
development, no mGluR antagonists are yet approved for
human use. The M1 muscarinic receptor antagonist,
dicyclomine, and the M4 antagonist, tropicamide, have also
been shown to partially improve abnormal behaviors and
seizure susceptibility in Fmr1-null mice [38,39].
The dopamine, glutamate, and acetylcholine systems in the
brain are all affected in mice lacking Fmr1. Dopamine in
particular is important for the initiation and reinforcement of
motivated behaviors. Mice lacking Fmr1 have increased
dopamine turnover [40] but decreased amphetamine-
stimulated dopamine release in the dorsal striatum [15], which
correlates with decreased sensitivity to amphetamine-induced
motor stereotypies [41]; as well as increased dopamine release
in the prefrontal cortex [15]. The postsynaptic effects of
dopamine D1 receptor activity on AMPA-type glutamate
receptor function are also reduced in both prefrontal cortex and
striatum [14,42].
There are relatively fewer behavioral or neurochemical
studies on limbic motor system function in Fmr1-null mice than
in hippocampus or neocortex. Given the critical involvement of
limbic circuitry in motivation and reinforcement, changes in
social integrative behavior and motor learning in FXS may be
affected by underlying deficits in limbic brain reward circuitry as
well as in cortex involved in memory and higher cognitive
functions. Although two studies have shown normal acquisition
of operant behavior using sucrose or food reinforcement in
Fmr1-null mice [10,43], the neural mechanisms underlying
motivation and reward have not been explored in depth in this
model. Imaging studies have identified alterations in both
morphology [44-46] and activation patterns [47,48] in the
striatum of FXS patients, but the function of dopaminergic
projections from the midbrain substantia nigra pars compacta
(SNc) and ventral tegmental area (VTA) to their forebrain
targets in the dorsal striatum and nucleus accumbens (NAc)
have been less extensively investigated than cortical circuits in
Fmr1-null mice. Drugs that directly affect the dopamine system,
including atypical neuroleptics such as aripiprazole, are of
interest for the management of affective and behavioral
symptoms in FXS [49,50]. Cholinergic mechanisms in
mesolimbic and nigrostriatal motor function, in which
interactions with the dopamine system shape striatal output
[51-54], are largely unexplored in this model.
The goal of the current study was to characterize limbic
motor circuitry with behavioral and neurochemical methods in
Fmr1-null mice. Intracranial self-stimulation (ICSS) is an
operant behavior in which animals perform a task for
reinforcement by electrical brain stimulation reward (BSR). The
predictable effects on BSR of drugs acting through dopamine,
glutamate, or acetylcholine receptors can be compared
between genotypes, and we have previously used this
approach to investigate pharmacological mechanisms in other
monogenic neurodevelopmental disorders [55]. We
hypothesize that Fmr1-null mice will show increased sensitivity
to drugs that enhance the rewarding value of BSR and,
conversely, decreased sensitivity to the reward-devaluing
effects of drugs that diminish BSR. Experiments measuring the
effects of the atypical neuroleptic aripiprazole, the mGluR5
antagonist MPEP, and the preferential M1 antagonist
trihexyphenidyl on locomotor behavior were also performed to
further differentiate drug effects on global motor function from
effects specific to operant behavior. To determine if absence of
Fmr1 alters dopaminergic neurons originating in the SNc and
VTA, tyrosine hydroxylase immunoreactivity was also
quantified by design-based stereology in midbrain histological
sections and by western blot in tissue homogenates from
dorsal striatum and NAc.
Methods
Ethics Statement
All procedures were approved by The Institutional Animal
Care and Use Committee (IACUC) of the University of North
Carolina at Chapel Hill (Protocol 12-146.0) and were conducted
according to the Guide for the Care and Use of Laboratory
Animals (NIH publication No. 85-23, revised 2011).
Mice
Male wild type (WT) and Fmr1-null mice (Fmr1-/Y) were bred
on site from founders generously provided by Dr. William
Greenough at the Beckman Institute, University of Illinois (see
56,57 for information on mouse origins). Mice were housed in
polycarbonate cages (28 × 17 × 14 cm) with wire lids and cob
bedding that was changed weekly. Mice used for ICSS (n = 31
WT, 29 Fmr1-/Y) and locomotor activity (n = 11 WT, 11 Fmr1-/Y)
experiments were housed individually while the mice for
tyrosine hydroxylase (TH) immunohistochemistry (n = 5 WT, 7
Fmr1-/Y) and protein determinations (n = 6 WT, 9 Fmr1-/Y) were
housed in groups of two to four. All mice had free access to
food and water and were allowed to acclimate to the vivarium
for at least one week prior to experiments. The vivarium was at
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21°C with a 12-hour light cycle (lights on at 8:00 PM); all
procedures were conducted in the dark phase between 8:30
AM and 4:30 PM. All behavioral experiments were performed
with the experimenter blinded to mouse genotype.
Drugs
Cocaine hydrochloride (Sigma-Aldrich, St. Louis MO) and the
mGluR5-selective antagonist, MPEP (6-methyl-2-
(phenylethynyl)pyridine hydrochloride, Tocris, Bristol UK), were
dissolved in saline, and doses were calculated as the free
base. The partially selective mAChR1 (M1) antagonist,
trihexyphenidyl (1-cyclohexyl-1-phenyl-3-(1-piperidyl)propan-1-
ol, Sigma-Aldrich), was dissolved in dH2O. The atypical
neuroleptic, aripiprazole (7-{4-[4-(2,3-
dichlorophenyl)piperazin-1-yl]butoxy}-3,4-
dihydroquinolin-2(1H)-one, generously provided by Bristol
Myers Squibb/Otsuka Pharmaceuticals), was dissolved in
glacial acetic acid and then diluted in a 2% Tween-20 solution
to a final pH of 4.3. All drugs were administered
intraperitoneally through a 27-gauge needle in a volume of 1ml/
100g body weight.
Electrode Implantation
Intracranial self-stimulation (ICSS) experiments were
conducted in adult (P55+) male mice that were anesthetized
(120 mg/kg ketamine and 18 mg/kg xylazine; Sigma-Aldrich)
and stereotaxically-implanted in the right medial forebrain
bundle at the level of the lateral hypothalamus (coordinates: AP
-1.3, ML -1.0, DV -5.2; [58]) with insulated monopolar stainless
steel electrodes (0.28 mm diameter; Plastics One, Roanoke
VA). The electrode was grounded to the skull with a stainless
steel screw and secured to the skull with dental cement.
Following surgery, animals were returned to their cages for one
week of recovery. ICSS electrode placements are shown in the
Supporting Information, Figure S1.
Intracranial Self-Stimulation
ICSS experiments were performed as previously described
[55] in sound-attenuating chambers (16 × 14 × 13 in;
MedAssociates, St Albans VT) containing an operant
conditioning chamber with a grid floor (ENV-005A;
MedAssociates), wheel manipulandum (ENV-113AM;
MedAssociates), and house light (ENV-315W; MedAssociates).
Electrical stimulation was controlled by MED-PC software for
Windows (v4.1; MedAssociates) and a stimulator
(PHM-150B/2; MedAssociates) connected to a swivel
commutator and insulated wire (Plastics One) that attached to
the stimulating electrode. A computer interface was connected
to each box to record responses (1 response = ¼ turn of the
wheel manipulandum), activate the house light, and issue
electrical current (brain stimulation reward, BSR).
Following recovery after surgery, mice were conditioned to
respond for BSR. Each stimulation consisted of a 500 ms train
of unipolar cathodal square-wave current pulses delivered at a
trial-dependent frequency with a 100 μs pulse width. During the
500 ms stimulation period, wheel responses were recorded but
did not earn additional stimulation. Each response was
accompanied by illumination of the house light for 500 ms as a
secondary reinforcer. Initially, optimal stimulus intensity to
sustain responding >40 responses/min at 158 Hz was
determined for each mouse (-60 to -190 μA) and was kept
constant for each mouse for all experiments.
Mice were then trained with a series of stimulus frequencies
in descending order from 158 Hz in 0.05 log10 increments (i.e.,
log10[112 Hz] = 2.05; log10[100 Hz] = 2.00, etc.). Each
frequency trial began with a 5 sec time-out, during which
responses earned no stimulation, followed by five non-
contingent priming stimulations (1 train/sec) and access to BSR
at that stimulus frequency for 50 sec, during which responses
were measured. All mice were trained to complete four series
of 15 trial frequencies (i.e., 1 hour) daily. The frequency range
was adjusted for each mouse such that only the highest 4-5
frequencies sustained responding, and was kept constant for
each mouse for all experiments. Maximum stimulus
frequencies ranged from 158 Hz to 100 Hz and did not differ
between genotypes (135 ± 4.1 Hz for WT vs. 139 ± 3.8 Hz for
Fmr1-/Y mice, p = 0.49). Training continued until daily BSR
threshold (θ0, [59]) calculated as the average of the second,
third, and fourth daily series, varied by less than ± 10% over
three consecutive days.
During each testing session, mice first responded in three
consecutive series of 15 descending frequency trials. Because
responding during the first series of each test day is variable,
daily baseline BSR thresholds (θ0, [59]) were averaged from
responses during the second and third series. After baseline
determinations, mice were removed from the conditioning
chambers, injected intraperitoneally with saline or drug vehicle
(for aripiprazole and trihexyphenidyl experiments), cocaine
(1.0, 3.0, or 10.0 mg/kg, i.p.), aripiprazole (0.03, 0.1, or 0.3
mg/kg, i.p.), MPEP (3.0, 5.6, or 10.0 mg/kg, i.p.), or
trihexyphenidyl (3.0, 10.0, or 30.0 mg/kg, i.p.), and returned to
the conditioning chambers for 1 hour (i.e., four 15-minute
response series). The order of each drug dose was counter-
balanced across mice and each drug dose was separated by a
vehicle injection. For experiments with aripiprazole only,
because pilot studies had indicated a longer onset of action
than for the other drugs tested, mice were injected and placed
in their home cage for 15 minutes before being returned to the
operant conditioning chamber. BSR threshold and maximum
operant response rate (MAX) were calculated for each post-
injection series and expressed as a percentage of the daily pre-
injection baseline.
Locomotor Activity
Adult male mice (P89-193, mean = P139) were placed in the
centers of 28 x 28 cm Plexiglas chambers (ENV-1510; Med
Associates) containing two sets of 16 pulse-modulated infrared
photobeams. Each photobeam interruption was relayed to a
computer running MedAssociates IV software that determined
the position of the mouse every 100 ms and calculated the total
distance traveled (cm). Locomotor behavior experiments were
conducted three days a week and separated by at least 48
hours. On each test session, the mice were placed into the
activity chambers for 45 min then removed, injected, and
returned to the chambers for 60 min in order to directly
compare drug effects on locomotor behavior and ICSS. As in
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ICSS experiments, for experiments with aripiprazole and its
vehicle only, mice were injected and placed in their home
cages for 15 min before being returned to the activity
chambers. The first three experimental days habituated the
mice to the apparatus and to handling required for injection.
Saline injections were given on the next three experimental
days to habituate the mice to intraperitoneal injection. For drug
testing, each drug dose was separated by at least one vehicle
injection. On the basis of results from ICSS experiments, all
mice received the following drug treatments in the following
order: cocaine (3.0 mg/kg, i.p.); aripiprazole (0.1 mg/kg, i.p.);
MPEP (5.6 mg/kg, i.p.); and trihexyphenidyl (10.0 mg/kg, i.p.),
cocaine (1.0 mg/kg), and cocaine (10.0 mg/kg).
Tyrosine Hydroxylase Immunohistochemistry
Experimentally naïve adult male mice (P120-126) were
deeply anesthetized (pentobarbital 120 mg/kg, i.p.) and
perfused transcardially with 0.1 M phosphate-buffered saline
(PBS, pH 7.4), followed by 4% paraformaldehyde in 0.1 M
PBS. All brains were post-fixed by submersion in the same
fixative for 24 hours, then cryoprotected in 10% sucrose for 24
hours, followed by 30% sucrose for 24 hours. Brains were
sectioned (50 μm, coronal) on a sliding microtome and stored
in cryoprotectant (1.0% w/v polyvinylpyrrolidone, 30% w/v
sucrose, and 30% v/v ethylene glycol in 0.1 M PBS).
Endogenous peroxidase activity was quenched with 1%
hydrogen peroxide in 0.1 M PBS for 30 minutes at room
temperature. Sections were blocked in 5% normal goat serum
(NGS) and 2% Triton X-100 in 0.1 M PBS for 24 hours at room
temperature, then incubated in rabbit-α-rat tyrosine
hydroxylase (TH) primary Ab (1:500; AB152; Millipore, Billerica
MA) in 2% NGS and 2% Triton for 4 days at 4°C. Sections
were washed (x3) in 0.1 M PBS and incubated with HRP-
conjugated goat-α-rabbit secondary Ab (1:250; 31460; Thermo
Scientific, Rockford IL) in 2% NGS and 2% Triton at room
temperature for 3 hours. Reaction product was visualized with
a DAB peroxidase substrate kit (SK-4100; Vector Laboratories,
Burlingame CA). Sections were mounted on potassium
dichromate/gelatin-subbed slides and counterstained with
cresyl violet for Nissl.
Stereological Estimation of Cell Numbers
The total number of TH-positive cells in the substantia nigra
pars compacta (SNc) and ventral tegmental area (VTA) were
estimated with design-based stereology using
StereoInvestigator v9.14 (MBF Bioscience, Williston VT) on a
Microphot FXA microscope (Nikon, Japan). Every fourth
section (section interval = 4) was immunostained and counted,
yielding on average eight midbrain sections per animal. The
borders of the SNc and the VTA at all rostrocaudal levels in the
midbrain were delineated at low (4x) magnification based on
the standard mouse atlas [58]. For purposes of this study, the
VTA and SNc were divided by a line connecting the medial
border of the medial lemniscus, dorsally, to the medial edge of
the corticospinal tract, ventrally, in all sections. Counting
frames (50 µm x 50 µm) were randomly placed and
systematically moved through a sampling grid (120 µm x 120
µm) by the software via a motorized stage (Ludl Electronic
Products, Hawthorne NY). An optical disector height of 15.0 µm
flanked by 2.0 µm guard zones on top and bottom was applied
to all counting frames based on average section shrinkage
estimates. Brightfield counting under direct visualization was
performed at 100x oil magnification (NA = 1.4). Estimates of
the total numbers of TH-immunostained neurons were
calculated using the optical fractionator method [60]. For all
samples, coefficients of error ≤ 0.10 (Gundersen, m = 1) were
accepted [61].
Tyrosine Hydroxylase Western Blots
Experimentally naïve adult male mice (P81-166, mean =
P114) were deeply anesthetized with isoflurane inhalation and
decapitated. Brains were collected, flash-frozen in isopentane
at -40°C, and stored at -80°C. Coronal tissue slabs (1.0 mm)
were collected from frozen brains using a cryostat at -15°C
(Leica, Buffalo Grove IL). Frozen tissue punches (1.0 mm dia.)
were taken from slabs containing the NAc and dorsal striatum
and homogenized by ultrasonification (Branson Ultrasonics,
Danbury CT) in a buffer containing 5% (w/v) sodium dodecyl
sulfate in 0.05M Tris buffer (pH = 7.4), a Complete Protease
Inhibitor Cocktail tablet (Roche, Florence SC) and 500 μL each
of phosphatase inhibitor 2 and 3 (Sigma-Aldrich). Protein
concentration was measured using a calorimetric assay kit
(Pierce BCA; Thermo Scientific). Protein (5 μg) was diluted 4:1
with lithium dodecyl sulfate sample buffer (40–70% glycerol)
and 10:1 with NuPAGE (Invitrogen, Carlsbad CA) and heated
at 70°C for 5 minutes. Samples were injected onto a Nu-Page
4-15% Tris-Glycine polyacrylamide gel (BioRad, Hercules CA)
for gel electrophoresis separation, and transferred to a
nitrocellulose membrane using an iBlot dry blotting system
(Invitrogen). Membranes were blocked with 3% bovine serum
albumin (Sigma-Aldrich) before incubation with rabbit-α-rat TH
primary Ab (1:2000; AB152, Millipore) overnight at 4°C.
Membranes were washed before incubation with an HRP-
conjugated goat-α-rabbit secondary Ab (1:10,000; Jackson
ImmunoResearch, West Grove PA) for 1 hour at room
temperature. Membranes were then incubated for 5 minutes in
Amersham ECL Prime Western Blotting Detection Reagent
(GE, Piscataway NJ). Bands were visualized on an
ImageQuant LAS4000 system (GE) and quantified using
optical density measurements (ImageQuantTL v7.0, GE). A
similar method was used to detect β-actin using a mouse
monoclonal anti-β-actin primary Ab (1:5000; Millipore) for 1
hour at room temperature and an HRP-conjugated goat-α-
mouse secondary Ab (1:10,000; Jackson ImmunoResearch) for
1 hour at room temperature. Data were expressed as ratios of
TH:β-actin for each sample.
Data Analysis
For ICSS experiments, statistical comparisons of baseline
BSR thresholds and maximum operant response rates (MAX)
were performed using Student’s t-tests for unmatched samples
(two-tailed). Comparisons of drug effects on BSR threshold and
MAX in WT and Fmr1-/Y mice were performed by two-way
repeated measures ANOVAs (dose x genotype) for each 15-
minute post-injection series followed by post hoc Bonferroni
corrected comparisons to control (vehicle or WT). When main
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effects of genotype but no dose x genotype interaction was
observed, one-way ANOVA for effect of dose was performed
independently for each genotype to determine differences from
vehicle injection. For locomotor behavior experiments,
comparisons of total distance traveled and change from
baseline activity were performed using two-way repeated
measures ANOVA (time x genotype) at each dose with
Bonferroni corrected post hoc comparisons to control. On the
habituation days, comparison of total distance traveled before
and after handling was performed with Student’s t-tests for
unmatched samples (two-tailed). In the case of cocaine, two-
way repeated measures ANOVA (dose x genotype) with
pairwise Bonferroni corrections post hoc were also performed.
For stereological estimates of TH+ SNc and VTA neurons and
for TH:β-Actin ratios in tissue homogenates of dorsal striatum
and NAc, Levene’s F-tests for equality of variance were
followed with Student’s t-tests for unmatched samples (two-
tailed). For all statistical comparisons, p < 0.05 was considered
significant.
Results
Baseline ICSS and Locomotor Behavior
Throughout all intracranial self-stimulation (ICSS)
experiments, mice showed frequency-dependent responding
for brain stimulation reward (BSR; Figure 1A). There was no
difference in sensitivity to BSR itself between genotypes, as
charge delivery at baseline BSR threshold frequency (θ0) was
similar in Fmr1-/Y (3.8 ± 0.37 x10-7 C) and WT mice (3.4 ± 0.23
x10-7 C, Figure 1B). However, maximum operant response
rates (MAX) were lower in Fmr1-/Y mice (t58 = 2.5; p = 0.015;
Figure 1C). Pre-injection baseline BSR thresholds remained
stable over the course of all ICSS experiments in both WT and
Fmr1-/Y mice (Supporting Information, Figure S2).
In open-field locomotion, Fmr1-/Y mice were less active than
WT mice during habituation to handling and the novel
apparatus on the first two days of testing. On Day 1, there was
a significant main effect of genotype (F1,153 = 10.7; p = 0.004;
Figure 1D), with Fmr1-/Y less active than WT mice across all 15-
minute pre- and post-handling test periods (p < 0.05), as well
as over the full 45 min before (t20 = 2.674; p = 0.015) and 60
min after handling (t20 = 2.676; p = 0.015; Figure 1D, inset). On
Day 2, there was a significant interaction between time and
genotype (F6,153 = 4.1; p < 0.001; Figure 1E), with less activity
for the first 75 minutes of testing and significantly lower total
activity in the 45-minute pre-handling habituation phase in
Fmr1-/Y mice (t20 = 4.9; p < 0.001; Figure 1E, inset). By Day 3 of
habituation, there was less total locomotion in the 45-minute
pre-handling phase, but no differences in activity after handling
(Figure 1F).
Pharmacological Sensitivity of BSR and Locomotor
Activity
Cocaine.  Cocaine increases the rewarding value of BSR,
measured as lowering of BSR threshold. Previous studies in
our laboratory have consistently shown that the maximal effect
of cocaine on ICSS occurs in the first 15 minutes after injection
in C57BL6/J mice [55,62,63]. There was a significant
interaction between cocaine dose and genotype on changes in
BSR threshold (F3,147 = 3.29; p = 0.02) in the first 15 minutes
after injection (Figure 2A). BSR thresholds were significantly
lower in Fmr1-/Y than WT mice after 1.0 mg/kg cocaine (p <
0.05) and approached significance after 3.0 mg/kg cocaine (p =
0.053). Cocaine only increased maximum operant response
rates for BSR (MAX) in the first 15 minutes in WT mice only
after the 10 mg/kg dose (Figure 2B). Significant effects of
cocaine dose on BSR threshold were found in all four 15-
minute testing periods after cocaine injection and on MAX in
WT but not Fmr1-/Y mice at time points after 16-30 minutes
following injection (Figures S3A and S4A and Tables S1 and
S2).
Total locomotor activity after saline injection did not differ
between Fmr1-/Y and WT mice, but significant interactions
between time and genotype were found following 1.0 (F5,131 =
3.17; p = 0.01), 3.0 (F5,131 = 4.37; p = 0.001) and 10.0 mg/kg
cocaine injections (F5,131 = 3.98; p = 0.002), with Fmr1-/Y mice
significantly less active than WT mice in the first 15 minutes
after 1.0 and 3.0 mg/kg (p < 0.05) and in the first 30 minutes
after 10.0 mg/kg cocaine (p < 0.05; Figure 2D, Figure S5).
There was a significant interaction between cocaine dose and
genotype (F3,87 = 3.44; p = 0.02) on locomotor activity after
cocaine injection relative to pre-injection baseline activity:
locomotor activity increased less in Fmr1-/Y than in WT mice
after 3.0 and 10.0 mg/kg cocaine (p < 0.05; Figure 2C).
Aripiprazole.  Like other neuroleptics, aripiprazole
decreases the rewarding value of BSR, evident as elevation of
BSR threshold. The onset of aripiprazole effects on ICSS was
slow, with maximal effects not seen until after 45-60 minutes
following injection (see Supporting Information, Figure S3B).
After 45 minutes post-injection, aripiprazole elevated BSR
threshold significantly less in Fmr1-/Y than in WT mice; main
effects of dose (F3,99 = 22.09; p < 0.001) and genotype (F1,99 =
6.67; p = 0.02), but no significant interaction of dose and
genotype, were found (Figure 3A). At this time point the 0.1
and 0.3 mg/kg aripiprazole doses significantly reduced MAX in
Fmr1-/Y (p < 0.05) but only 0.3 mg/kg reduced MAX in WT mice
(F1,99 = 11.02; p = 0.003; Figure 3B, Figure S4B).
There was no significant difference between genotypes in
total locomotor activity following either vehicle or aripiprazole
injection, although Fmr1-/Y mice showed a non-significant trend
towards less activity than WT mice after 0.1 mg/kg ARI (F1,131 =
4.21; p = 0.053; Figure 3C, Figures S6A and S6B). However,
relative to pre-injection baseline activity, there were no
significant differences in relative reductions of locomotor
activity between genotypes following 0.1 mg/kg aripiprazole
(Figure 3D).
MPEP.  Previous studies have shown that MPEP devalues
BSR in rats [64], but no prior reports of its effects on ICSS in
mice exist. In our hands, MPEP potentiated BSR, and this
effect was more evident in Fmr1-/Y than WT mice at 31-45
minutes after MPEP injection (F3,75 = 3.36; p = 0.03; Figure 4A,
Figure S3C), at which point 5.6 mg/kg MPEP lowered BSR
threshold in Fmr1-/Y mice (p < 0.05) but no dose of MPEP
affected BSR threshold in WT mice. There was a significant
main effect of genotype but no effect of MPEP dose on MAX at
all time points after injection (Figure 4B, Figure S4C and Table
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S2); regardless of MPEP dose, Fmr1-/Y mice had significantly
less reduction in MAX than WT mice.
Total locomotor activity did not differ between genotypes
following saline injection, but Fmr1-/Y mice were significantly
less active than WT mice (F5,131 = 2.77; p = 0.02) in the first 30
min after 5.6 mg/kg MPEP injection (p < 0.05; Figure 4C,
Figures S6C and S6D). However, relative to pre-injection
baseline, there was no significant difference in locomotor
simulation of Fmr1-/Y and WT mice after 5.6 mg/kg MPEP, with
no main effect of genotype and no significant interaction
between time and genotype following either saline or MPEP
injection (Figure 4D).
Trihexyphenidyl.  There is no previous information available
on the specific effects of the partially M1-selective muscarinic
antagonist, trihexyphenidyl, on BSR. In our hands, 10 mg/kg
trihexyphenidyl consistently lowered BSR threshold in WT mice
(p < 0.05) but not in Fmr1-/Y mice (Figure 5A) with a significant
interaction of dose and genotype (F3,75 = 4.38; p = 0.008). No
trihexyphenidyl dose affected BSR threshold in the Fmr1-/Y
mice at any time point after injection (Figure S3D and Table
S1). There was also a significant interaction between
trihexyphenidyl dose and genotype on MAX in the first 45
minutes after injection; 30.0 mg/kg trihexyphenidyl consistently
lowered MAX in WT mice (p < 0.05), but MAX was unaffected
by any dose in Fmr1-/Y mice (Figure 5B, Figure S4D and Table
S2).
Total locomotor activity did not differ between genotypes
following vehicle injection, and while Fmr1-/Y mice were
Figure 1.  Comparison of ICSS and locomotor behavior in wild type (WT, white circles) and Fmr1-/Y mice (red circles).  A.
Both Fmr1-/Y and WT mice responded for BSR in a frequency-dependent manner. Values are mean number of responses per 50 sec
access to BSR at each stimulus frequency ± SEM. B. BSR sensitivity expressed as electrical charge delivery at baseline BSR
threshold frequency (θ0) did not differ between WT (white bars) and Fmr1-/Y mice (red bars). Values are mean charge in Coulombs ±
SEM. C. Baseline maximum operant response rates were lower in Fmr1-/Y mice than WT mice. Values are mean maximum number
of responses ± SEM. * = p < 0.05 vs. WT. D-F. Habituation to the novel locomotor apparatus and handling in WT and Fmr1-/Y mice.
On Day 1 (D) Fmr1-/Y mice were less active at all time points before (15-45 min) and after handling (60-105 min), and had lower
cumulative total locomotion before and after handling (inset). On Day 2 (E) Fmr1-/Y mice were less active prior to (inset) and for 30
min following handling. By Day 3 (F), total locomotion remained lower in Fmr1-/Y mice prior to handling but no difference in
locomotion was seen after handling (inset). Dashed lines indicate handling time points. Values are mean distance traveled ± SEM.
Asterisks (*) indicate p < 0.05 vs. WT.
doi: 10.1371/journal.pone.0077896.g001
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significantly less active than WT mice during minutes 15-30 of
the baseline period preceding 10 mg/kg trihexyphenidyl (time x
genotype F5,131 = 3.39; p = 0.007; post hoc p < 0.05), no
genotype differences were found following trihexyphenidyl
injection (Figure 5C, Figures S6E and S6F). Relative to pre-
injection baseline activity, there was no significant difference
between genotypes after vehicle injection; however, following
10.0 mg/kg trihexyphenidyl, Fmr1-/Y mice were significantly
more stimulated than WT mice (F1,87 = 6.10; p = 0.02; Figure
5D).
Tyrosine Hydroxylase
Stereological estimates of TH+ neurons in the SNc and VTA
of wild-type C57BL6/J mice obtained from our colony were in
agreement with previously published values [65]. Fewer TH+
SNc neurons were found in Fmr1-/Y than in WT mice (t9 = 2.56;
p = 0.03), but numbers of TH+ neurons in the VTA did not differ
between genotypes (t9 = -0.12; p = 0.91; Figure 6A). There
were no significant differences in TH content of either dorsal
striatum (t12 = 0.43; p = 0.67) or NAc (t13 = -1.02; p = 0.32)
between WT and Fmr1-/Y mice (Figure 6B).
Discussion
The present study investigated reward and motor function in
the Fmr1-/Y mouse model of fragile X syndrome (FXS) by
measuring the sensitivity of brain stimulation reward (BSR) and
locomotor activity, respectively, to drugs that affect dopamine,
muscarinic acetylcholine, and metabotropic glutamate
receptors. We also measured the numbers of neurons
expressing tyrosine hydroxylase (TH), the rate-limiting enzyme
in dopamine biosynthesis, in the midbrain, and measured TH
expression in forebrain targets of projections from those
neurons. Our data suggest that absence of Fmr1 does not
affect intrinsic sensitivity of mesolimbic circuits to brain
stimulation reward (BSR), which we have previously shown to
Figure 2.  Effects of cocaine on ICSS and locomotor behavior in wild type (WT, white circles) and Fmr1-/Y mice (red
circles).  Changes in BSR threshold (A) and maximum operant response rate (MAX, B) in the first 15 minute series after i.p.
cocaine injections are shown. Values are expressed as mean percentages of pre-injection baselines ± SEM. C. Mean change in
locomotion (± SEM) as a percentage of pre-injection baseline activity after injection of saline (V) or cocaine (1.0, 3.0, or 10.0 mg/kg
i.p.) in the first 15 minutes after injection. For A-C, asterisks (*) indicate p < 0.05 vs. vehicle (V); daggers (†) indicate p < 0.05 vs.
WT (dose x genotype interaction post hoc). D. Mean distance traveled (± SEM) before and after injection of saline (VEH) or cocaine
(COC, 1.0, 3.0, or 10.0 mg/kg i.p.) in 15-minute intervals. Shading indicates post-injection time points. Daggers (†) indicate p < 0.05
vs. WT (time x genotype interaction post hoc).
doi: 10.1371/journal.pone.0077896.g002
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be increased in mice lacking the maternal allele of ubiquitin
ligase 3a (Ube3am-/p+), a model for Angelman syndrome [55].
However, like Ube3am-/p+ mice, Fmr1-/Y mice appear to have
reduced activity of nigrostriatal motor circuits that are involved
with the initiation of motor activity, expressed as decreased
spontaneous locomotion. In contrast to Ube3am-/p+ mice, loss of
Fmr1 is associated with reduced numbers of dopaminergic
neurons in the substantia nigra pars compacta (SNc). Our
behavioral data show that loss of Fmr1 differentially alters
reward and motor responses to specific pharmacological
challenges. Drugs used to treat the behavioral symptoms of
FXS may differentially impact, and have unintended
consequences on, reward activity mediated primarily by
mesolimbic circuits and motor activity mediated largely, but not
exclusively, through nigrostriatal circuits. Loss of FMRP
function may therefore exaggerate some of these differential
drug effects.
Although intrinsic sensitivity to BSR was similar between
Fmr1-/Y and wild type mice, there were consistent differences in
reactions of Fmr1-/Y mice to drug challenges that are known to
Figure 3.  Effects of the atypical neuroleptic aripiprazole
on ICSS and locomotor behavior in wild type (WT, white
circles) and Fmr1-/Y mice (red circles).  Changes in BSR
threshold (A) and maximum operant response rate (MAX, B)
46-60 minutes after i.p. aripiprazole injections are shown.
Values are expressed as mean percentages of pre-injection
baselines ± SEM.
Asterisks (*) indicate p < 0.05 vs. vehicle (V). C. Mean distance
traveled (± SEM) before and after injection of vehicle (VEH) or
aripiprazole (ARI, 0.1 mg/kg i.p.) in 15-minute intervals.
Shading indicates post-injection time points. D. Mean change
in locomotion (± SEM) as a percentage of pre-injection
baseline activity for 60 minutes after injection of vehicle (VEH)
or aripiprazole (ARI, 0.1 mg/kg i.p.).
doi: 10.1371/journal.pone.0077896.g003
affect sensitivity to positive reinforcement. In general, Fmr1-/Y
mice appeared to be more sensitive to the reward potentiating
effects of cocaine and less sensitive to the anhedonic effects of
the atypical neuroleptic, aripiprazole. Cocaine potentiation of
brain stimulation reward (BSR) is extremely well characterized
and robust. While BSR involves distributed neural circuits in the
brainstem, basal forebrain, and frontal cortex, dopamine
release in the nucleus accumbens (NAc) is necessary for the
rewarding effects associated with both BSR and natural
incentives such as food, as well as drugs of abuse [66]. Drugs
that increase extracellular dopamine availability increase the
potency of BSR, measured as a lowering of BSR threshold.
Conversely, dopamine antagonists, such as neuroleptics,
devalue BSR and raise BSR threshold. While aripiprazole has
previously been shown to elevate BSR thresholds in rats [67],
this is the first report of its effects on ICSS in a mouse model.
The absence of changes in number of ventral tegmental area
(VTA) TH+ neurons and TH content in the NAc suggests that
Figure 4.  Effects of the mGluR5-selective antagonist
MPEP on ICSS and locomotor behavior in wild type (WT,
white circles) and Fmr1-/Y mice (red circles).  Changes in
BSR threshold (A) and maximum operant response rate (MAX,
B) 31-45 minutes after i.p. MPEP injections are shown. Values
are expressed as mean percentages of pre-injection baselines
± SEM.
Asterisks (*) indicate p < 0.05 vs. vehicle (V); daggers (†)
indicate p < 0.05 vs. WT (dose x genotype interaction post
hoc). C. Mean distance traveled (± SEM) before and after
injection of saline (VEH) or MPEP (5.6 mg/kg i.p.) in 15-minute
intervals. Shading indicates post-injection time points. Daggers
(†) indicate p < 0.05 vs. WT (time x genotype interaction post
hoc). D. Mean change in locomotion (± SEM) as a percentage
of pre-injection baseline for 60 minutes after injection of saline
(VEH) or MPEP (5.6 mg/kg i.p.).
doi: 10.1371/journal.pone.0077896.g004
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structural loss of dopaminergic projections is less likely to
account for these findings than functional changes in dopamine
release or dopamine receptor function in the NAc and other
mesocorticolimbic sites, such as prefrontal cortex (PFC) or the
VTA itself.
Dopamine facilitates long-term potentiation (LTP) of
excitatory synaptic transmission by increasing synthesis and
surface expression of AMPA-type glutamate receptors through
D1 receptor signaling [68]. Production of cAMP and enhanced
GluA1 phosphorylation following D1 stimulation are reduced in
PFC and striatum of Fmr1-/Y mice and can be rescued with
FMRP expression [14]. Glutamatergic PFC projections drive
firing of GABAergic medium spiny neurons (MSNs), the
principal output cells of both NAc and dorsal striatum. D1
receptors contribute to the development of LTP [69] and
mGluR5 receptor signaling contributes to synaptic long-term
depression (LTD) in NAc MSNs [70]. Decreasing NAc activity is
the principal common neural pathway by which reward
Figure 5.  Effects of the partially M1-selective antagonist
trihexyphenidyl on ICSS and locomotor behavior in wild
type (WT, white circles) and Fmr1-/Y mice (red
circles).  Changes in BSR threshold (A) and maximum operant
response rate (MAX, B) 31-45 minutes after i.p. trihexyphenidyl
injections are shown. Values are expressed as mean
percentages of pre-injection baselines ± SEM. Asterisks (*)
indicate p < 0.05 vs. vehicle (V); daggers (†) indicate p < 0.05
vs. WT (dose x genotype interaction post hoc). C. Mean
distance traveled (± SEM) before and after injection of dH2O
(VEH) or trihexyphenidyl (THX, 10.0 mg/kg i.p.) in 15-minute
intervals. Shading indicates post-injection time points. Daggers
(†) indicate p < 0.05 vs. WT (time x genotype interaction post
hoc). D. Mean change in locomotion (± SEM) as a percentage
of pre-injection baseline for 60 minutes after injection of dH2O
(VEH) or trihexyphenidyl (THX, 10.0 mg/kg i.p.).
doi: 10.1371/journal.pone.0077896.g005
perception is mediated and translated into motivated behavior
[71,72]. It is therefore possible that the enhanced potency of
cocaine to potentiate BSR is due to a combination of
decreased excitatory drive from PFC to NAc and/or decreased
intrinsic excitability of NAc medium spiny neurons in Fmr1-/Y
mice. Experiments are currently underway in our laboratory to
test these hypotheses.
Normal extrapyramidal motor function requires a balance
between dopaminergic and cholinergic activity in the dorsal
striatum, such that increasing dopamine or decreasing
acetylcholine has hyperkinetic effects and, conversely,
decreasing dopamine or increasing acetylcholine has
hypokinetic effects. Both the reduced initial locomotion and the
reduced potency of cocaine to stimulate locomotor activity we
observed in Fmr1-/Y mice is consistent with decreased numbers
of dopaminergic neurons found in the SNc, although this was
not reflected in decreased TH content in their dorsal striatal
targets. However, Fulks et al. [41] have shown that while tissue
content of dopamine and its primary metabolites, DOPAC and
HVA, is unchanged in the dorsal striatum of Fmr1-/Y mice,
electrically-stimulated dopamine release measured with fast-
scan cyclic voltammetry in striatal slices is decreased; and this
decrease is not associated with changes in D2 autoreceptor
function. These findings together with ours predict a
parkinsonian motor phenotype in this model, which is observed
Figure 6.  Anatomical and biochemical correlates of
dopaminergic function in wild type (WT, white bars) and
Fmr1-/Y mice (red bars).  A. Mean numbers of tyrosine
hydroxylase (TH) expressing neurons (± SEM, top) in the
substantia nigra pars compacta (SNc) and ventral tegmental
area (VTA) of WT and Fmr1-/Y mice estimated with design-
based stereology. Numbers of mice are indicated in each
column. Ventral midbrain image (bottom left) is magnified 4x
and inset showing TH staining (bottom right) 40x. Asterisks (*)
indicate p < 0.05 vs. WT. cp = cerebral peduncle; fr =
fasciculus retroflexus; ml = medial lemniscus. B. Mean ratio of
TH to β-Actin staining intensity expressed as percentage of
mean WT values (± SEM, top) in western blots of homogenates
from dorsal striatum and nucleus accumbens (NAc) of WT and
Fmr1-/Y mice. Numbers of mice are indicated in each column.
Representative bands (bottom) are shown for each column
above.
doi: 10.1371/journal.pone.0077896.g006
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in older FXS patients. CGG expansion in the FMR1 gene of
premutation FXS carriers results in progressive
neurodegeneration associated with parkinsonism in fragile X-
associated tremor/ataxia syndrome (FXTAS). However, to our
knowledge decreased numbers of dopaminergic SNc neurons
has not been previously reported either in post-mortem brains
of FXS patients or in Fmr1-/Y mice. In summary, our data
suggest that dopaminergic function is differentially altered in
mesolimbic and nigrostriatal pathways in the Fmr1-/Y mouse
model of FXS, the balance of effects facilitating reward function
and diminishing motor function.
While the importance of cholinergic actions in the striatum is
appreciated, and anticholinergics have been in routine clinical
use for extrapyramidal movement disorders for decades, the
function of large, aspiny, tonically active cholinergic
interneurons (TANs) remains much less understood than other
striatal cell types, such as MSNs and GABAergic fast-spiking
interneurons (FSIs), particularly in the NAc. TANs synapse
extensively with MSNs and are the primary source of
acetylcholine in both the dorsal striatum and NAc. As is the
case for their role in motor function, the euphoric and rewarding
effects of muscarinic anticholinergics have been appreciated
for centuries, but the exact mechanisms by which
anticholinergics function in mesolimbic brain reward circuitry
are not well understood. Recent studies have suggested that
TANs may integrate thalamostriatal and corticostriatal input
[51] and local FSI function [54,73] to regulate firing of MSNs
[74]. Most of what is known regarding TAN function has been
learned from experiments in the dorsal striatum, and with a few
exceptions [52,74] these neurons have been largely
uninvestigated in the NAc.
The net behavioral effects of the M1 antagonist,
trihexyphenidyl, in WT mice were potentiation of BSR within a
narrow dose range, suppression of maximum operant response
rate without a change in threshold at the highest dose tested
(30 mg/kg), and locomotor stimulation at a dose that
potentiated BSR (10 mg/kg). In contrast, trihexyphenidyl did not
potentiate BSR in Fmr1-/Y mice at any dose, and the locomotor
stimulation we observed at 10 mg/kg was significantly
enhanced in Fmr1-/Y compared to WT mice, consistent with a
parkinsonian motor phenotype and further illustrating the
dissociation of reward and motor effects in Fmr1-/Y mice.
Trihexyphenidyl has no effect by itself on dopamine release in
the NAc, but increases cocaine-potentiated NAc dopamine
release and cocaine-stimulated locomotor activation [53],
suggesting that cholinergic regulation of mesolimbic circuitry
normally keeping NAc dopamine release in check is
disinhibited by M1 antagonism, and that this function may be
impaired in Fmr1-/Y mice. Acetylcholine signaling through
M2/M4 receptors on TANs indirectly reduces dopamine release
[52], but signaling through M1 receptors on presynaptic
terminals increases excitability of dopaminergic neurons by
inhibiting local GABA release in the VTA [75]. Neither
mechanism fully explains our present behavioral results with
trihexyphenidyl. We are currently investigating how M1 activity
in NAc MSNs differs between Fmr1-/Y and WT mice. Given that
M1 receptors are also Gq-coupled and signal through PLC, it is
possible that M1 function is also altered in NAc MSNs of mice
lacking FMRP.
Group I mGluR receptors (mGluR1/5) are distributed
ubiquitously throughout the brain and act as a brake on
glutamatergic excitation. The highly selective mGluR5
antagonist, MPEP, has anxiolytic potency in rodent models and
potentiated BSR in our hands, with larger effects in Fmr1-/Y
than in WT mice. MPEP also transiently but significantly
stimulated locomotor activity, although relative motor
stimulation compared to baseline activity was similar between
genotypes. In the dorsal striatum, mGluR5 receptors mediate
both postsynaptic AMPA receptor endocytosis [76], which is
enhanced in hippocampal neurons of Fmr1-/Y mice [77], and
presynaptic endocannabinoid (eCB)-dependent LTD [78]. It has
been shown that mGluR5-coupled retrograde eCB signaling
through Gq-coupled activation of PLC and diacylglycerol lipase
is disrupted in both dorsal striatum [79] and NAc [80], and, in
contrast to hippocampus, mGluR5-dependent LTD is absent
from NAc MSNs in Fmr1-/Y mice [80], a finding that we have
replicated in our laboratory (unpublished observations). In
contrast to MSNs, mGluR-dependent LTD is expressed
postsynaptically in dopaminergic VTA neurons through
increased synthesis and membrane insertion of AMPA receptor
GluA2 subunits [81], and preliminary data in our laboratory also
suggest that mGluR5-LTD in VTA neurons is enhanced in
Fmr1-/Y mice (unpublished observations). Thus, the predicted
actions of MPEP on reward and reinforcement are complex,
and while mGluR5 activity acts to decrease glutamatergic
excitation in different cell types through both pre- and
postsynaptic mechanisms, the effect of loss of FMRP on
mGluR mechanisms, and ultimately on neuronal activity, likely
differs in different elements of brain reward circuitry.
Experiments are currently underway in our laboratory
investigating both mGluR5 and mAChR1 activity in the VTA
and NAc to test these hypotheses.
Although systemic drug administration cannot determine
exact mechanisms for the differences we observe in Fmr1-/Y
mice, our current findings replicate those of other behavioral
and electrophysiological studies reporting that Fmr1 deletion
affects the dopaminergic, glutamatergic, and cholinergic
neurotransmitter systems and extend these differences to the
regulation of brain reward, which may have clinical implications
for patients with FXS. Behavioral therapy is a mainstay in the
treatment of children with neurodevelopmental disorders,
including FXS. Discrete trial-based learning [82] is a widely-
employed therapeutic method in which specific desirable
behaviors are rewarded and this approach, by definition, relies
upon intact brain mechanisms of reward perception and their
ability to reinforce specific behaviors so that the motivation to
engage in these behaviors is subsequently enhanced. Many
drugs used in the treatment of patients with
neurodevelopmental disabilities influence limbic motor function
such that their concomitant use could reduce the effectiveness
of behavioral therapies by interfering with reward perception or
behavioral motivation. Our preclinical findings suggest that the
effects of these drugs may differ in individuals with FXS and
may therefore inform clinical practice by suggesting behavioral
reinforcement and drug regimens specific to FXS patients. In
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addition, altered reward processing has important implications
not only for how individuals with FXS respond to behaviorally-
based therapies but also for their socialization, which could be
impacted by deficits in social reward or enhanced social
aversion.
The current experiments used acute drug dosing to study
behavioral pharmacology in Fmr1-/Y mice, but one of the
broader aims of these investigations is to determine if selective
drugs acting on dopamine, glutamate, or acetylcholine
receptors can ameliorate ongoing abnormal behaviors, with the
ultimate goal of developing better treatments for individuals
with FXS. mGluR5 antagonists are in ongoing clinical trials in
FXS patients, but to date no controlled clinical trials have been
performed with aripiprazole (Abilify™) or anticholinergics
approved for human use, such as trihexyphenidyl (Artane™) or
benztropine (Cogentin™). It is unclear if any one drug acting at
any one receptor will reduce all FXS symptoms, and more
likely that effects at more than one drug target will be
necessary to correct different aspects of abnormal behaviors. It
is also unclear if drug treatments will need to be continuously
administered or if beneficial adaptations to time-limited drug
therapy will persist, and at what developmental age or ages
such drug therapies will be effective. Preclinical investigation of
both basic neural mechanisms and the effects of drugs on
behavior in the Fmr1-/Y mouse model remains an important tool
in drug discovery for FXS.
Supporting Information
Figure S1.  ICSS electrode placements. Confirmation of
ICSS electrode tip locations. Brains from mice used for ICSS
experiments were fixed by intracardiac perfusion under deep
pentobarbital anesthesia, removed, sectioned, and stained with
cresyl violet for Nissl to determine electrode placements. The
most ventral point of each electrode tract was determined by
visual inspection. All ICSS electrodes were implanted on the
right: tip positions are plotted on the left for WT mice (grey
circles) and on the right for Fmr1-/Y mice (red circles) for clarity.
(TIF)
Figure S2.  Baseline BSR threshold stability over course of
ICSS experiments. Daily baseline BSR thresholds in wild type
(WT, white circles) and Fmr1-/Y mice (red circles). Pre-injection
baseline BSR thresholds remained stable, and no significant
changes were observed in mice of either genotype, over the
course of the ICSS experiments. Values are expressed as
mean daily baseline BSR threshold ± SEM.
(TIF)
Figure S3.  Changes in BSR threshold following acute drug
treatments. Changes in BSR threshold following acute drug
treatment in wild type (WT, white circles) and Fmr1-/Y mice (red
circles). A. Cocaine lowered BSR threshold in a dose-
dependent manner to a greater extent in Fmr1-/Y than WT mice.
B. Conversely, the atypical neuroleptic aripiprazole elevated
BSR threshold in a dose-dependent manner less in Fmr1-/Y
than WT mice. C. The mGluR5-selective antagonist MPEP
lowered BSR threshold to a similar extent in Fmr1-/Y and WT
mice immediately after injection (0-15 min), but was more
effective longer into the 60-minute test session in Fmr1-/Y than
in WT mice (31-45 min). D. The partially M1-selective
antagonist trihexyphenidyl lowered BSR threshold over a
narrow dose range (10 mg/kg) in WT mice, but did not change
threshold in Fmr1-/Y mice at any dose. All values are expressed
as mean percentage of pre-injection baseline BSR threshold ±
SEM. Asterisks (*) indicate p < 0.05 vs. vehicle (V); daggers (†)
indicate p < 0.05 vs. WT (dose x genotype interaction post
hoc). Complete statistics are shown in Table S1.
(TIF)
Figure S4.  Changes in maximum operant response rate
(MAX) following acute drug treatments. Changes in
maximum operant response rate (MAX) following acute drug
treatment in wild type (WT, white circles) and Fmr1-/Y mice (red
circles). A. Cocaine increased MAX only at the highest dose
tested (10 mg/kg) in WT but not Fmr1-/Y mice. B. The atypical
neuroleptic aripiprazole reduced MAX in a dose-dependent
manner to a greater extent in WT mice at earlier time points
after injection (15-30 min), but to a similar extent in Fmr1-/Y and
WT mice thereafter. Significant main effects of both
aripiprazole dose and genotype but no interactions of dose and
genotype on MAX were found from 31-75 min after injection. C.
The mGluR5-selective antagonist MPEP did not significantly
affect MAX in either Fmr1-/Y or WT mice. Significant main
effects of genotype but no effects of MPEP dose or interactions
of dose and genotype on MAX were found at all four post-
injection time points. D. The partially M1-selective antagonist
trihexyphenidyl reduced MAX in a dose-dependent manner in
WT but not Fmr1-/Y mice. Significant main effects of genotype
on MAX were found at all four post-injection time points after
trihexyphenidyl. All values are expressed as mean percentage
of pre-injection baseline MAX ± SEM. Asterisks (*) indicate p <
0.05 vs. vehicle (V); daggers (†) indicate p < 0.05 vs. WT (dose
x genotype interaction post hoc). Complete statistics are shown
in Table S2.
(TIF)
Figure S5.  Changes in total distance traveled following
acute cocaine. Locomotor behavior before and 60 minutes
following acute cocaine administration (COC, 1.0, 3.0, or 10.0
mg/kg i.p.) in wild type (WT, white circles) and Fmr1-/Y mice
(red circles). Data are expressed as mean total distance
traveled ± SEM in 1 min intervals. Shading indicates post-
injection time points.
(TIF)
Figure S6.  Changes in total distance traveled following
acute drug treatments. Locomotor behavior before and 60
minutes following acute drug (right panels) or vehicle
administration (left panels) in wild type (WT, white circles) and
Fmr1-/Y mice (red circles). A,B. Distance traveled after injection
of the atypical neuroleptic aripiprazole (ARI, 0.1 mg/kg i.p.) or
its vehicle (2% Tween 20). C,D. Distance traveled after
injection of the mGluR5-selective antagonist MPEP (5.6 mg/kg
i.p.) or saline (VEH). E,F. Distance traveled after injection of
the partially M1-selective antagonist trihexyphenidyl (THX, 10.0
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mg/kg i.p.) or its vehicle (dH2O). Data are expressed as mean
total distance traveled ± SEM in 1 min intervals. Shading
indicates post-injection time points.
(TIF)
Table S1.  Statistical analysis of changes in BSR threshold
following acute drug treatments. Statistical analysis of
changes in BSR threshold following acute treatment with
cocaine, aripiprazole, MPEP, and trihexyphenidyl, data for
which are shown in Figure S3. Two-way ANOVA (dose x
genotype) with one repeated measure (dose) was performed at
each 15 minute testing interval after drug injection. df =
degrees of freedom; n = number of comparisons.
(DOC)
Table S2.  Statistical analysis of changes in MAX following
acute drug treatments. Statistical analysis of changes in
maximum operant response rate (MAX) following acute
treatment with cocaine, aripiprazole, MPEP, and
trihexyphenidyl, data for which are shown in Figure S4. Two-
way ANOVA (dose x genotype) with one repeated measure
(dose) was performed at each 15 minute testing interval after
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